GENEVA, June 19 -- NOVARTIS AG filed a patent application (IB2025/061515) for “REMIBRUTINIB FOR USE IN THE TREATMENT OF MYASTHENIA GRAVIS”. With publication no. WO/2026/104987, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: A61K 31/505
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....